NHS app to become new ‘front door' for appointments, screenings and test results
The NHS app is set to become the primary communication channel for patients, offering appointment reminders, screening invitations, and test results directly to their smartphones.
The Department of Health and Social Care has announced a significant investment in the app, with the goal of saving the health service £200 million over the next three years.
This initiative aims to reduce the reliance on traditional postal services, avoiding the need to send at least 50 million NHS letters annually.
Health Secretary Wes Streeting likened the transition from analogue to digital communication to everyday conveniences such as "online banking or ordering a takeaway".
This £50 million investment will facilitate the delivery of 270 million messages through the NHS app this year, marking an increase of 70 million compared to the previous financial year.
Push notifications will serve as appointment reminders, addressing the issue of missed appointments, which amounted to approximately eight million in elective care during 2023/24.
More than 11 million people in the UK currently log into the NHS app every month, while almost 20 million are opted in to receive healthcare messages from the app.
Where app messaging is not available, particularly for elderly patients without smartphones, communications will be sent via text message and then by letter as a last resort and phone lines will be freed up.
It is hoped the changes will give patients better access to manage their healthcare journey and make informed decisions about their care.
NHS app services, which were launched in December 2018, are now used in 87% of hospitals across England.
Last month, NHS England announced millions of patients would be able to get 'Amazon-style' tracking updates on their prescriptions through the app, to check if their medicines are ready to collect or have been despatched for delivery.
Health Secretary Wes Streeting said: 'People are living increasingly busy lives and want to access information about their health at the touch of a button, rather than having to wait weeks for letters that often arrive too late.
'This Government is bringing our analogue health service into the digital age, so that being a patient in the NHS is as convenient as online banking or ordering a takeaway.
'The NHS still spends hundreds of millions of pounds on stamps, printing, and envelopes. By modernising the health service, we can free up huge amounts of funding to reinvest in the front line.
'Through the investment and reform in our Plan for Change, we will make the NHS App the front door to the health service and put power in the hands of patients.'
Rachel Power, chief executive of the Patient's Association, said: 'This major upgrade to the NHS App marks a significant step in modernising how patients receive information, from test results to screening invitations.
'This was a recommendation from our Digital Coalition and realises changes that patients have asked for.
'We welcome this investment and the ambition behind it. Success for any digital innovation will be the implementation of the Digital Inclusion Plan and working directly with patients and communities.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Beloved NYC eatery Jacob's Pickles shuttered over roaches, rats and sewage
Upper West Side eatery Jacob's Pickles was abruptly shuttered this week following a slew of icky code violations. The Department of Health temporarily closed the Southern-style dining hotspot after the place showed evidence of rats and roaches. The restaurant was also cited for having an 'improper, inadequate, or unapproved' sewage disposal system. An inspection report revealed that the venue, located at 509 Amsterdam Ave. between 84th and 85th Streets, also allegedly failed to properly protect 'food, supplies, or equipment' from possible contamination sources. The shutdown took effect Wednesday with a statement from the restaurant claiming they'll be back open come Monday. 'While unexpected, we're genuinely grateful this issue was brought to our attention,' the statement read. 'With the guidance of the health department, we uncovered underlying structural issues that contributed to unforeseen facility maintenance challenges. 'The safety of our guests and staff is always our top priority, and we will not reopen until every concern is resolved in full compliance with NYC Health Code standards,' the statement concluded. The restaurant's website stated that Jacob's Pickles was closed for renovations and 'will open in a few days.' Jacob's Pickles has had a C rating with the Department of Health since December. Owner Jacob Hadjigeorgis said in May 2024 he would move the American restaurant to a new location at 688 Columbus Ave., between 93rd and 94th Streets, after which he planned to open a new bar, Velvet Cowboy, inside the space Jacob's Pickles had occupied. It's unclear if Hadjigeorgis' plans have changed.
Yahoo
an hour ago
- Yahoo
Doctors try 'poo pills' to flush out dangerous superbugs
UK doctors are attempting to clear dangerous superbug infections using "poo pills" containing freeze-dried faeces. The stool samples come from healthy donors and are packed with good bacteria. Early data suggests superbugs can be flushed out of the dark murky depths of the bowel and replaced with a mix of healthy gut bacteria. It is a new approach to tackling infections that resist antibiotics, which are thought to kill a million people each year. The focus is on the bowels which are "the biggest reservoir of antibiotic resistance in humans" says Dr Blair Merrick, who has been testing the pills at Guys and St Thomas' hospitals. Drug-resistant superbugs can escape their intestinal home and cause trouble elsewhere in the body – such as urinary tract or bloodstream infections. "So there's a lot of interest in 'can you get rid of them from the gut?'," says Dr Merrick. The idea of poo-pills isn't as far-fetched as it might seem. Faecal transplants – also known as a trans-poo-tion - are already approved for treating severe diarrhoea caused by Clostridium difficile bacteria. But scientists noticed hints that faecal transplants for C. difficile also seemed to get rid of superbugs. Microbiome podcast: Manipulating Our Hidden Half New research has focused on patients who had an infection caused by drug-resistant bacteria in the past six months. They were given pills made from faeces which people had donated to a stool bank. Each stool sample is tested to ensure it does not contain any harmful bugs, undigested food is removed and then it is freeze dried into a powder. This is stored inside a pill that can pass through the stomach unscathed and reach the intestines where it dissolves to release its poopy powdery payload. The trial has taken place on 41 patients at Guy's and St Thomas' hospitals in London to lay the groundwork for a large-scale study. It showed patients were up for taking a poo pill and the donated bacteria were still being detected in the bowels at least a month later. Dr Merrick says there are "really promising signals" that poo pills could help tackle the rising scourge of superbugs and that donor bacteria could be going to microbial war with the superbugs as they compete over food and space on the lining of the gut and either rid the body of them completely or "reduce them down to a level that doesn't cause problems". The study also suggests the array of gut bacteria becomes more varied after the therapy. This is a sign of good health and "may well be promoting colonisation resistance" so it is harder for new infectious bugs to get in. "It's very exciting. There's a real shift from 20 years ago where all bacteria and viruses were assumed to do you harm; to now where we realise they are completely necessary to our overall health," says Dr Merrick. Earlier this week scientists showed the good bacteria our bodies meet – in the hours after we are born – seem to halve the risk of young children being admitted to hospital with lung infections. First bacteria we ever meet can keep us out of hospital More than half your body is not human Our body's own human cells are outnumbered by the bacteria, fungi and others that live inside us - known as the microbiome. This has led to research implicating the microbiome in everything from Crohn's disease to cancer to mental health. If poo pills are proven to work against superbugs in larger studies then the researchers think they could be used for both treatment and prevention in people at risk. Medical procedures that suppress the immune system - including cancer therapies and organ transplants - can make the body more vulnerable. "A lot of these individuals come to a lot of harm from drug resistant organisms," Dr Merrick. The UK's drugs regulator – the Medicines and Healthcare Products Agency – said there were more than 450 microbiome medicines currently in development. "Some of them will success, so I do think we will seem them coming through quite soon," said Dr Chrysi Sergaki, the head of microbiome research at the MHRA. "We could potentially, in the future, replace antibiotics with microbiome [therapies] - that's the big picture, so there's a lot of potential."
Yahoo
2 hours ago
- Yahoo
Is Hims & Hers Health a Smart Buy Right Now?
Hims & Hers is the newest darling disrupting the telemedicine space. While shares have jumped 157% over the last year, Wall Street analysts don't seem overly bullish on the stock. Despite impressive results in the business, Hims & Hers has a high short interest -- making a short-squeeze a possibility. 10 stocks we like better than Hims & Hers Health › When it comes to stocks that continue to beat the market, my guess is that your mind goes straight to companies leading the charge in artificial intelligence (AI). Sure, stocks such as Palantir Technologies or CoreWeave remain red-hot in a strong technology sector. But smart investors understand that there are myriad opportunities beyond the usual suspects in tech. One company that has emerged as a new favorite among investors is telemedicine business Hims & Hers Health (NYSE: HIMS). With shares up 157% over the last 12 months as of market close June 4, Hims & Hers Health looks like the next monster growth stock at the intersection of healthcare and technology. Let's assess the state of Hims & Hers' business and then take a look at what Wall Street thinks. Is buying shares of this telemedicine darling a good idea right now? Read on to find out. Hims & Hers is a telemedicine platform that offers patients access to a variety of medications, including for skin care, anxiety, sexual health, and even weight loss. At the core of the company's business model is a subscription platform. At the end of the first quarter, Hims & Hers boasted 2.4 million subscribers, which represented an increase of 38% year over year. This translated into revenue of $586 million for the quarter, up by a jaw-dropping 111% year over year. By keeping its business primarily online, Hims & Hers can benefit in a couple of ways. First, subscription revenue is recurring and therefore carries high gross margins. Second, by keeping its user base using its offerings, the company has the flexibility to spend less on marketing and invest in other areas, such as technology or research and development, in an effort to bolster customer acquisition strategies. Per management's vision, Hims & Hers is doubling down on investments in AI to get a better sense of its customer data. This could be a savvy move, as it may help the company unlock new expansion opportunities. While the ideas above paint a picture of a fast-growing, disruptive new solution in the healthcare space, Wall Street doesn't seem totally sold on Hims & Hers just yet. Over the last month, a number of equity research analysts, including Piper Sandler, Citigroup, Bank of America, and Morgan Stanley, have each maintained ratings of neutral, sell, underperform, or equal-weight. Another way of looking at this is that among some of the largest banks on Wall Street, none seem to have a compelling buy rating on Hims & Hers stock. In addition, the average price estimate among analysts for Hims & Hers stock is roughly $48, implying 12% downside from trading levels as of June 4. Given Wall Street's somewhat bearish sentiment, what could be fueling the stock's seemingly unstoppable rally? I think the company's high short interest could be the cause of the rise in its stock. Per the chart above, roughly 35% of Hims & Hers float is sold short. Investors who short a stock are betting its price will fall. Short interest of 10% or more is considered unusually high. Not only is Hims & Hers' short interest much higher than the usual benchmarks, it's also rising. A high short interest can fuel volatility and even a rise in a stock's price if investors who are shorting a stock need to buy shares in the company to return the borrowed shares and close out their position. This is known as short covering, and it often leads to pronounced increases in a stock for a fleeting period of time, adding to volatility. You might be more familiar with these dynamics as a short squeeze. Despite notable subscriber growth and expanding markets, Hims & Hers stock exhibits too much volatility for my liking, and with that, comes a high degree of uncertainty. At first glance, I can understand what makes Hims & Hers look like an appealing investment. Telemedicine represents a compelling opportunity at the intersection of healthcare and technology, and Hims & Hers has certainly proven that it can consistently acquire users and monetize them. Moreover, the prospects that AI presents in the healthcare space more broadly shouldn't be discounted -- further validating the vision management has for Hims & Hers' long-term growth. Nevertheless, I struggle to look past the meme stock type of behavior exhibited here. While some investors have certainly made money owning this stock, I am suspicious if their profits were sparked by the right reasons. Said differently, I view Hims & Hers as more of a swing trading stock (timing is everything) as opposed to a sound long-term opportunity at this time. For these reasons, I would pass on Hims & Hers at the moment. While I'm intrigued by the company's potential, I think shares have run up considerably and would not be surprised to see some contraction in the share price sooner than later. Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $669,517!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $868,615!* Now, it's worth noting Stock Advisor's total average return is 792% — a market-crushing outperformance compared to 171% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Bank of America is an advertising partner of Motley Fool Money. Citigroup is an advertising partner of Motley Fool Money. Adam Spatacco has positions in Palantir Technologies. The Motley Fool has positions in and recommends Bank of America, CrowdStrike, Hims & Hers Health, and Palantir Technologies. The Motley Fool has a disclosure policy. Is Hims & Hers Health a Smart Buy Right Now? was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
